Lack of effect of methylene blue in the SOD1 G93A mouse model of amyotrophic lateral sclerosis

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Lougheed, Rosamond ^a   Turnbull, John ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCINE; METHYLENE BLUE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GENE DOSAGE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; SURVIVAL RATE; SURVIVAL TIME; ANIMAL; CONGENIC STRAIN; DISEASE MODEL; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; SURVIVAL; TREATMENT OUTCOME;

ANIMALIA; MUS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; MALE; METHYLENE BLUE; MICE; MICE, CONGENIC; SUPEROXIDE DISMUTASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 80053585258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023141     Document Type: Article

References (41)

1. Rosen D, Siddique T, Patteron D, Figlewicz D, Sapp P, et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59-62.
2. Yang Y, Hentati A, Deng H, Dabbagh O, Sasaki T, et al. (2001) The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 29: 160-165.
3. Munch C, Sedlmeier R, Meyer T, Homberg V, Sperfeld A, et al. (2004) Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 63: 724-726.
4. Nishimura A, Mitne-Neto M, Silva H, Richieri-Costa A, Middleton S, et al. (2004) A mutation in the vesicle trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am J Hum Genet 75: 822-831.
5. Greenway M, Andersen P, Russ C, Ennis S, Cashman S, et al. (2006) ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat Genet 38: 411-413.
6. Neumann M, Sampathu D, Kwong L, Truax A, Micsenyi M, et al. (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314: 130-133.
7. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, et al. (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Bioph Res Co 351: 602-611.
8. Vance C, Rogelj B, Hortobagyi T, De Vos K, Nishimura A, et al. (2009) Mutations in FUS, an RNA Processing Protein, Cause Familial Amyotrophic Lateral Sclerosis Type 6. Science 323: 1208-1211.
9. Kwiatkowski T, Bosco D, Leclerc A, Tamrazian E, Vanderburg C, et al. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 23: 1205-1208.
10. Meyer T, Schwan A, Dullinger J, Brocke J, Hoffman K, (2005) Early-onset ALS with long-term survival associated with spastin gene mutation. Neurology 65: 141-143.
11. McGowan D, Scelsa S, Waldron M, (2001) An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology 57 (6): 1094-1097.
12. Silva M, Leite C, Alamy A, Chimelli L, Andrada-Serpa M, (2005) ALS syndrome in HTLV-I infection. Neurology 65: 1332-1333.
13. Wiklund L, Basu S, Micescu A, Wiklund P, Ronquist G, et al. (2007) Neuro- and cardioprotective effects of blockade of nitric oxide action by administration of methylene blue. Ann NY Acad Sci 1122: 231-244.
14. Wiedemann F, Winkler K, Kuznetsov A, Bartels C, Vielhaber S, et al. (1998) Impairment of mitochondrial function in skeletal muscles of patients with amyotrophic lateral sclerosis. J Neurol Sci 156: 65-72.
15. Mayer B, Brunner F, Schmidt K, (1993) Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 45: 367-374.
16. Almer G, Vukosavic S, Romero N, Przedborski S, (1999) Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial Amyotrophic Lateral Sclerosis. J Neurochem 72: 2415-2425.
17. Beal M, Ferrante R, Browne S, Matthews R, Kowall N, et al. (1997) Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann Neurol 42: 644-654.
18. Ferrante R, Shinobu L, Schulz J, Matthews R, Thomas C, et al. (1997) Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Ann Neurol 42: 326-334.
19. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, et al. (2008) Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB 22: 703-712.
20. Jilani K, Panee J, He Q, Berry M, Li P, (2007) Overexpression of Selenoprotein H Reduces HT22 Neuronal Cell Death after UVB Irradiation by Preventing Superoxide Formation. Int J Biol Sci 3 (4): 198-204.
21. Papp L, Holmgren A, Khanna K, (2010) Selenium and selenoproteins in health and Disease. Antioxid Redox Sign 12 (7): 793-795.
22. Andrus P, Fleck T, Gurney M, Hall E, (1998) Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 71: 2041-2048.
23. Barber S, Mead R, Shaw P, (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762: 1051-1067.
24. Harrington C, Rickard J, Horsley D, Harrington K, Hindley K, et al. (2008) Methylethioninium chloride (MTC) acts as a tau aggregation inhibitor (TAI) in a cellular model and reverses tau pathology in transgenic mouse models of Alzheimer's disease. Alzheimer's Dement 4: T120-T121.
25. Gura T, (2008) Hope in Alzheimer's fight emerges from unexpected place. Nat Med 14: 894.
26. Yang W, Sopper M, Leystra-Lutz C, Strong M, (2003) Microtubule associated tau protein positive neuronal and glial inclusions in amyotrophic lateral sclerosis. Neurology 61: 1766-1773.
27. Strong M, Yang W, Strong W, Leystra-Lantz C, Jaffe H, et al. (2006) Tau protein hyperphosphorylation in sporadic ALS with cognitive impairment. Neurology 66: 1770-1771.
28. Sasaki S, Iwata M, (1996) Impairment in fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis. Neurology 47: 535-540.
29. Fischer L, Culver D, Tennant P, Davis A, Wang M, et al. (2004) Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 185: 232-240.
30. National Toxicology Program (2008) NTP toxicology and carcinogenesis studies of methylene blue trihydrate (CAS No. 7220-79-3) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl Toxicol Prog Tech Rep Ser 540: 1-244.
31. McComas A, Upton A, Sica R, (1973) Motoneuron disease and ageing. Lancet 29: 1477-1480.
32. Scott S, Kranz J, Cole J, Lincecum J, Thompson K, et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Sc. 9: 4-15.
33. Wooley C, Sher R, Kale A, Frankel W, Cox G, et al. (2005) Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32: 43-50.
34. Hayworth C, Gonzalez-Lima F, (2009) Pre-symptomatic detection of chronic motor deficits and genotype prediction in congenic B6.SOD1G93A ALS mouse model. Neuroscience 164: 975-985.
35. Kolb S, Sutton S, Schoenberg D, (2010) RNA processing defects associated with diseases of the motor neuron. Muscle Nerve 41 (1): 5-17.
36. Oz M, Lorke DE, Hasan M, Petroianu GA, (2010) Cellular and molecular actions of methylene blue in the nervous system. Med Res Rev 31: 93-117.
37. O'Leary J, Qingyou L, Marinec P, Blair L, Congdon E, et al. (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice requires neuroprotection and reduced soluble tau burden. Mol Neurodegener 5: 45-55.
38. Walter-Sack I, Rengelshausen J, Oberwittler H, Burhenne J, Mueller O, et al. (2009) High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol 65: 179-189.
39. Peter C, Hongwan D, Kupfer A, Lauterburg B, (2000) Pharmacokinetics and organ distribution of intravenous and oral methylene blue. Eur J Clin Pharmacol 56: 247-250.
40. Gurney M, (1997) The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J Neurol Sci 152: S67-S73.
41. Gurney M, Pu H, Chiu A, Dal Canto M, Polchow C, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1772-1775.